EP3755355A4 - IN VIVO EXPANSION OF NK AND DC CELLS TO PROVIDE AN IMMUNE RESPONSE - Google Patents

IN VIVO EXPANSION OF NK AND DC CELLS TO PROVIDE AN IMMUNE RESPONSE Download PDF

Info

Publication number
EP3755355A4
EP3755355A4 EP19757891.7A EP19757891A EP3755355A4 EP 3755355 A4 EP3755355 A4 EP 3755355A4 EP 19757891 A EP19757891 A EP 19757891A EP 3755355 A4 EP3755355 A4 EP 3755355A4
Authority
EP
European Patent Office
Prior art keywords
expansion
cells
immune response
vivo delivering
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19757891.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3755355A1 (en
Inventor
Guy Sauvageau
Sandra COHEN
Jean Roy
Silvy LACHANCE
Jean-Sébastien DELISLE
Jalila CHAGRAOUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Universite de Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal filed Critical Universite de Montreal
Publication of EP3755355A1 publication Critical patent/EP3755355A1/en
Publication of EP3755355A4 publication Critical patent/EP3755355A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1315—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from cardiomyocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19757891.7A 2018-02-20 2019-02-20 IN VIVO EXPANSION OF NK AND DC CELLS TO PROVIDE AN IMMUNE RESPONSE Pending EP3755355A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862632733P 2018-02-20 2018-02-20
PCT/CA2019/050208 WO2019161494A1 (en) 2018-02-20 2019-02-20 Expansion of nk and dc cells in vivo mediating immune response

Publications (2)

Publication Number Publication Date
EP3755355A1 EP3755355A1 (en) 2020-12-30
EP3755355A4 true EP3755355A4 (en) 2022-01-05

Family

ID=67687479

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19757891.7A Pending EP3755355A4 (en) 2018-02-20 2019-02-20 IN VIVO EXPANSION OF NK AND DC CELLS TO PROVIDE AN IMMUNE RESPONSE

Country Status (6)

Country Link
US (1) US12011460B2 (https=)
EP (1) EP3755355A4 (https=)
JP (1) JP7467358B2 (https=)
CN (1) CN112135618A (https=)
CA (1) CA3091865A1 (https=)
WO (1) WO2019161494A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212187B (zh) * 2018-09-06 2022-01-11 东华大学 一种检测多环芳烃的类酶联免疫试剂盒及其应用
CN112851678B (zh) * 2019-11-28 2022-04-19 广东医科大学 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤转移作用
CN112851679B (zh) * 2019-11-28 2022-03-25 广东医科大学 2，4，7-三取代嘧啶并吲哚化合物抗肿瘤作用
AU2020409437A1 (en) * 2019-12-18 2022-07-14 Universite De Montreal Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds
CN113350356B (zh) * 2021-05-26 2022-12-27 广东湛江海洋医药研究院 2,4,7-三取代嘧啶并吲哚化合物抗肿瘤耐药作用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018297A1 (en) * 1995-11-13 1997-05-22 The Regents Of The University Of Michigan Functional human hematopoietic cells
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
US8440177B2 (en) * 2005-12-07 2013-05-14 Centro de Investigaciones Energéticas, Medioambientales y Technológicas Method of treating graft versus host disease using adipose derived mesenchymal stem cells
CA2858069A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
CA3002066A1 (en) * 2015-10-15 2017-04-20 Celularity Inc. Natural killer cells and ilc3 cells and uses thereof
AU2018200424A1 (en) * 2010-07-13 2018-02-08 Anthrogenesis Corporation Methods of generating natural killer cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090029982A1 (en) 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2011056739A1 (en) 2009-11-03 2011-05-12 Glaxosmithkline Llc Compounds and methods
PT2807165T (pt) 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
JP6460991B2 (ja) 2012-09-12 2019-01-30 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗菌剤として使用するための三環式ジャイレース阻害剤
CA2946446C (en) 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
NZ733213A (en) 2014-12-31 2022-10-28 Celularity Inc Natural killer cells and uses thereof
WO2017120597A1 (en) 2016-01-07 2017-07-13 Ripple Foods, Pbc Product analogs or components of such analogs and processes for making same
CA3024273A1 (en) 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018297A1 (en) * 1995-11-13 1997-05-22 The Regents Of The University Of Michigan Functional human hematopoietic cells
US8440177B2 (en) * 2005-12-07 2013-05-14 Centro de Investigaciones Energéticas, Medioambientales y Technológicas Method of treating graft versus host disease using adipose derived mesenchymal stem cells
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
AU2018200424A1 (en) * 2010-07-13 2018-02-08 Anthrogenesis Corporation Methods of generating natural killer cells
CA2858069A1 (en) * 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
CA3002066A1 (en) * 2015-10-15 2017-04-20 Celularity Inc. Natural killer cells and ilc3 cells and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019161494A1 *

Also Published As

Publication number Publication date
CN112135618A (zh) 2020-12-25
CA3091865A1 (en) 2019-08-29
US20210085714A1 (en) 2021-03-25
US12011460B2 (en) 2024-06-18
EP3755355A1 (en) 2020-12-30
JP7467358B2 (ja) 2024-04-15
JP2021521262A (ja) 2021-08-26
WO2019161494A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
EP3755355A4 (en) IN VIVO EXPANSION OF NK AND DC CELLS TO PROVIDE AN IMMUNE RESPONSE
EP3728563A4 (en) IMPROVED IMMUNE EFFECTOR CELLS AND USE OF THEM
PL3368658T3 (pl) Namnażanie komórek T gamma delta rezydujących w tkankach nie-krwiotwórczych i zastosowania tych komórek
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
IL273918A (en) Trispecific proteins and methods of use
IL269380A (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
DK3707159T5 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
SI3892628T1 (sl) Ultra dolgo delujoči inzulin-fc-fuzijski proteini in postopki za uporabo
EP3523416A4 (en) METHOD AND COMPOSITIONS RELATING TO NK CELL AND ANTI-PDL1 CANCER THERAPIES
DK3322425T3 (da) Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
EP3668972A4 (en) CONSTRUCTED DNASE ENZYMS AND THEIR USES IN THERAPY
IL277036A (en) Expression of human FOXP3 in genetically engineered T cells
CO2018006297A2 (es) Composiciones y métodos para disminuir la expresión de tau
DK3827838T3 (da) Hæmning af cytokin-induceret sh2-protein i nk-celler
PL4190355T3 (pl) Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
IL277039A (en) Expression of FOXP3 in edited CD34 cells
EP3634437A4 (en) COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
EP3582856A4 (en) COMPOSITIONS AND METHODS OF ACTIVATING NK CELLS
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
PL3721227T3 (pl) Receptor węchu biorący udział w percepcji zapachu piżma i jego zastosowanie
EP3359650A4 (en) ACTIVATION AND EXPANSION OF CELLS
IL290297A (en) Modified cytotoxic t cells and methods of use thereof
EP3410892A4 (en) CHAIR AND COMPONENTS
EP3347449A4 (en) ZELLEX PANSION PROCEDURE AND THERAPEUTIC COMPOSITIONS
EP3604546A4 (en) SYSTEM OF PROTEIN EXPRESSION IN A PLANT CELL AND ASSOCIATED USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAUVAGEAU, GUY

Inventor name: DELISLE, JEAN-SEBASTIEN

Inventor name: ROY, JEAN

Inventor name: LACHANCE, SILVY

Inventor name: CHAGRAOUI, JALILA

Inventor name: COHEN, SANDRA

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039635

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20211206

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/0784 20100101ALI20211130BHEP

Ipc: C12N 5/0783 20100101ALI20211130BHEP

Ipc: C12N 5/071 20100101ALI20211130BHEP

Ipc: C07D 487/04 20060101ALI20211130BHEP

Ipc: A61P 37/04 20060101ALI20211130BHEP

Ipc: A61P 31/12 20060101ALI20211130BHEP

Ipc: A61K 35/28 20150101ALI20211130BHEP

Ipc: A61K 35/17 20150101ALI20211130BHEP

Ipc: A61K 35/15 20150101ALI20211130BHEP

Ipc: A61K 35/545 20150101AFI20211130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231031

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20260203